FDA announces recall of guidewire component used during angiography procedures

The U.S. Food and Drug Administration announced Friday that Medtronic is recalling certain models of its Angiographic Guidewire Component due to sterilization issues.

Medtronic’s recall includes five models distributed between Nov. 23, 2007, and March 29, 2021, the FDA said in a statement. The Class 1 recall is the most serious designation and indicates the use of these devices may cause serious injury or death.

“Medtronic Vascular is recalling the Angiographic Guidewire Component because devices were not sterilized before being shipped directly to hospitals,” the FDA said July 2. “If patients are exposed to the non-sterile device, serious adverse events could occur such as infection, sepsis, and death.”

Guidewires are used during angiography or other interventional procedures to help clinicians place cardiac catheters. The recall applies to more than 54,000 components in the U.S.

“There have been two complaints, and no reported injuries or deaths related to this issue,” the statement read. “However, there is potential for underreporting as physicians may not have been aware that devices were non-sterile.

Medtronic sent an urgent recall letter to its affected customers on May 4 urging providers to identify and quarantine all unused, affected guidewires. An amended letter sent out on June 3 advised customers to report adverse events or quality problems to FDA and Medtronic.

Read the full statement here.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

Trimed Popup
Trimed Popup